Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market.
Opioid abuse legislation.
Issues relating to prescription drug pricing.
Issues relating to the removal of Opana ER from the market.
Issues relating to illegal marketing of phenobarbital.
Issues related to FDA approval of adrenaline.
Issues relating to drug compounding.
Issues relating to incentives for life sciences research.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
Patent reform.
Issues relating to misuse of the inter pares review process.
Issues relating to Mass Torts and Class Action Reform.
Duration: February 1, 2011
to
February 28, 2018
General Issues: Health Issues , Taxation/Internal Revenue Code , Copyright/Patent/Trademark , Torts , Government Issues
Spending: about $850,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2011: House of Representatives, U.S. Senate, House of Representatives,, Office of Natl Drug Control Policy (NDCP),
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Joseph Gibson Chief Minority Counsel, House Judiciary Committee 2007-2008
Chief of Staff, Rep. Lamar Smith 2005-2007
Chief Legislative Counsel & Parliamentarian, House Judiciary
Committee 2003-2005
Deputy Asst Attorney General/Office of Leg Affairs 2002-2003
Counsel for Legislative & Intergovernmental Affairs Anti-
Trust Division, DOJ 2001-2002
Chief Antitrust Counsel, House Judiciary Comm. 1997-2001
Counsel, House Judiciary Comm. 1995-1997
Chief Minority Counsel, House Judiciary Committee 2007-2008; Chief of Staff, Rep. Lamar Smith 2005-2007; Chief Legislative Counsel & Parliamentarian, House Judiciary Committee 2003-2005; Deputy Asst. Attorney General, Office of Leg. Affairs 2002-2003
Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997
Chief Minority Counsel, House Judiciary Comm.
House Judiciary Comm. 2003-2005
Counsel for Legislative and Intergovernmental
Chief Anti-Trust Counsel, House Judiciary
Counsel, House Judiciary Comm. '95-'97
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2018
The Gibson Group, LLC terminated an engagement in which they represented Endo Pharmaceuticals Inc. on April 20, 2018.
Original Filing: 300953439.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market.
Opioid abuse legislation.
Issues relating to prescription drug pricing.
Issues relating to the removal of Opana ER from the market.
Issues relating to illegal marketing of phenobarbital.
Issues related to FDA approval of adrenaline.
Issues relating to drug compounding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
Patent reform.
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues relating to Mass Torts and Class Action Reform.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on Jan. 22, 2018.
Original Filing: 300932992.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market.
Opioid abuse legislation.
Issues relating to prescription drug pricing.
Issues relating to the removal of Opana ER from the market.
Issues relating to illegal marketing of phenobarbital.
Issues related to FDA approval of adrenaline.
Issues relating to drug compounding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General corporate tax reform.
Issues relating to incentives for life sciences research.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Issues relating to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
Patent reform.
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues relating to Mass Torts and Class Action Reform.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2017
In Q3, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on Oct. 20, 2017.
Original Filing: 300911973.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market.
Opioid abuse legislation.
Issues relating to prescription drug pricing.
Issues relating to the removal of Opana ER from the market.
Issues relating to illegal marketing of phenobarbital.
Issues related to FDA approval of adrenaline.
Issues relating to drug compounding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General corporate tax reform.
Issues relating to incentives for life sciences research.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
Patent reform.
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues relating to Mass Torts and Class Action Reform.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2017
In Q2, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on July 20, 2017.
Original Filing: 300893305.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market.
Opioid abuse legislation.
Issues relating to prescription drug pricing.
Issues relating to the removal of Opana ER from the market.
Issues relating to illegal marketing of phenobarbital.
Issues related to FDA approval of adrenaline.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
Patent reform.
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues relating to Mass Torts and Class Action Reform.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on April 20, 2017.
Original Filing: 300871899.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market.
Opioid abuse legislation.
Issues relating to prescription drug pricing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
Patent reform.
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues relating to Mass Torts and Class Action Reform.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $60,000. The report was filed on Jan. 23, 2017.
Original Filing: 300854781.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
House 21st Century Cures bill (Senate companion which includes NIH and FDA issues).
H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market.
H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016.
S.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160: Protect Medical Innovation Act of 2015.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
H.R. 9: The Innovation Act.
S. 1137: Protecting American Talent and Entrepreneurship Act of 2015 (PATENT Act).
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2016
In Q3, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $20,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834688.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
House 21st Century Cures bill (Senate companion which includes NIH and FDA issues).
H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market.
H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016.
S.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160: Protect Medical Innovation Act of 2015.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
H.R. 9: The Innovation Act.
S. 1137: Protecting American Talent and Entrepreneurship Act of 2015 (PATENT Act).
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2016
In Q2, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on July 20, 2016.
Original Filing: 300816414.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
House 21st Century Cures bill (Senate companion which includes NIH and FDA issues).
H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market.
H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016.
S.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160: Protect Medical Innovation Act of 2015.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
H.R. 9: The Innovation Act.
S. 1137: Protecting American Talent and Entrepreneurship Act of 2015 (PATENT Act).
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2016
In Q1, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on April 20, 2016.
Original Filing: 300797611.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA.
Issues related to Opioids.
Issues relating to Medicare Part D rebates.
Compounding and drug supply chain legislation.
House 21st Century Cures bill (Senate companion which includes NIH and FDA issues).
H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160: Protect Medical Innovation Act of 2015.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
H.R. 9: The Innovation Act.
S. 1137: Protecting American Talent and Entrepreneurship Act of 2015 (PATENT Act).
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2015
In Q4, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on Jan. 20, 2016.
Original Filing: 300778150.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to Medicare Part D rebates.
Compounding and drug supply chain legislation.
H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160: Protect Medical Innovation Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
H.R. 9: The Innovation Act.
S. 1137: Protecting American Talent and Entrepreneurship Act of 2015 (PATENT Act).
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2015
In Q3, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on Oct. 20, 2015.
Original Filing: 300759307.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to Medicare Part D rebates.
Compounding and drug supply chain legislation.
H.R.471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160: Protect Medical Innovation Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
H.R. 9: The Innovation Act.
S. 1137: Protecting American Talent and Entrepreneurship Act of 2015 (PATENT Act).
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on July 20, 2015.
Original Filing: 300741790.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to Medicare Part D rebates.
Compounding and drug supply chain legislation.
H.R.471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160: Protect Medical Innovation Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
H.R. 9: The Innovation Act.
Issues relating to misuse of the inter pares review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on April 20, 2015.
Original Filing: 300722118.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
Compounding and drug supply chain legislation.
H.R.471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160: Protect Medical Innovation Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
H.R. 9: The Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2014
In Q4, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on Jan. 6, 2015.
Original Filing: 300704634.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
Compounding and drug supply chain legislation.
H.R. 3204: Drug Quality and Security Act.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to eliminating Medicare coverage for vacuum erection systems.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 523/S. 232: Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements, including S. 214: Preserve Access to Affordable Generics Act.
H.R. 3309: Innovation Act.
S. 1720: Patent Transparency and Improvements Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2014
In Q3, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Inc. (Formerly Known As Endo Health Solutions, Inc.) , earning $30,000. The report was filed on Oct. 14, 2014.
Original Filing: 300682850.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
Compounding and drug supply chain legislation.
H.R. 3204: Drug Quality and Security Act.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 523/S. 232: Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements, including S. 214: Preserve Access to Affordable Generics Act.
H.R. 3309: Innovation Act.
S. 1720: Patent Transparency and Improvements Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2014
In Q2, The Gibson Group, LLC lobbied for Endo Health Solutions, Inc. , earning $30,000. The report was filed on July 8, 2014.
Original Filing: 300666271.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
Compounding and drug supply chain legislation.
H.R. 3204: Drug Quality and Security Act.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 523/S. 232: Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements, including S. 214: Preserve Access to Affordable Generics Act.
H.R. 3309: Innovation Act.
S. 1720: Patent Transparency and Improvements Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2014
In Q1, The Gibson Group, LLC lobbied for Endo Health Solutions, Inc. , earning $30,000. The report was filed on April 2, 2014.
Original Filing: 300645397.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
Compounding and drug supply chain legislation.
H.R. 3204: Drug Quality and Security Act.
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 523/S. 232 - Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements, including S. 214: Preserve Access to Affordable Generics Act.
H.R. 3309: Innovation Act.
S. 1720: Patent Transparency and Improvements Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2013
In Q4, The Gibson Group, LLC lobbied for Endo Health Solutions, Inc. , earning $30,000. The report was filed on Jan. 11, 2014.
Original Filing: 300624460.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
Compounding and drug supply chain legislation.
H.R. 3204: Drug Quality and Security Act.
Issues relating to products containing high doses of acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 523/S. 232 - Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements, including S. 214: Preserve Access to Affordable Generics Act.
H.R. 3309: Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2013
In Q3, The Gibson Group, LLC lobbied for Endo Health Solutions, Inc. , earning $30,000. The report was filed on Oct. 1, 2013.
Original Filing: 300601896.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
H.R. 486 - Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
Compounding and drug supply chain legislation.
H.R. 3204: Drug Quality and Security Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 523/S. 232 - Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
Legislation relating to abusive patent litigation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2013
In Q2, The Gibson Group, LLC lobbied for Endo Health Solutions, Inc. , earning $40,000. The report was filed on July 22, 2013.
Original Filing: 300585833.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
H.R. 486 - Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 523/S. 232 - Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
Legislation relating to abusive patent litigation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2013
In Q1, The Gibson Group, LLC lobbied for Endo Health Solutions, Inc. (Formely known as Endo Pharmaceuticals Holdings, LLC , earning $30,000. The report was filed on April 10, 2013.
Original Filing: 300551802.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
H.R. 486 - Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 523/S. 232 - Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2012
In Q4, The Gibson Group, LLC lobbied for Endo Health Solutions, Inc. , earning $30,000. The report was filed on Jan. 14, 2013.
Original Filing: 300527982.xml
Lobbying Issues
S. 319 - Pharmaceutical Market Access and Drug Safety Act of 2011.
H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012.
S. 3187 - Food and Drug Administration Safety and Innovation Act.
Issues relating to bioequivalence and related administrative procedures.Issues relating to DEA quotas for controlled substances.
Oversight of DEA.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Agencies Lobbied
U.S. House of Representatives,
Lobbying Issues
H.R. 3010 - Regulatory Accountability Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2012
In Q3, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Holdings, Inc. , earning $30,000. The report was filed on Oct. 12, 2012.
Original Filing: 300505816.xml
Lobbying Issues
S. 319 - Pharmaceutical Market Access and Drug Safety Act of 2011.
H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012.
S. 3187 - Food and Drug Administration Safety and Innovation Act.
Issues relating to bioequivalence and related administrative procedures.Issues relating to DEA quotas for controlled substances.
Oversight of DEA.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Agencies Lobbied
U.S. House of Representatives,
Lobbying Issues
H.R. 3010 - Regulatory Accountability Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2012
In Q2, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Holdings, Inc. , earning $30,000. The report was filed on July 18, 2012.
Original Filing: 300488355.xml
Lobbying Issues
S. 319 - Pharmaceutical Market Access and Drug Safety Act of 2011.
H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012.
S. 3187 - Food and Drug Administration Safety and Innovation Act.
Issues relating to bioequivalence and related administrative procedures.Issues relating to DEA quotas for controlled substances.
Oversite of DEA.
Issues relating to prescription drug abuse.
Agencies Lobbied
U.S. House of Representatives,
Lobbying Issues
H.R. 3010 - Regulatory Accountability Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2012
In Q1, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Holdings, Inc. , earning $30,000. The report was filed on April 18, 2012.
Original Filing: 300463816.xml
Lobbying Issues
S. 319 - Pharmaceutical Market Access and Drug Safety Act of 2011
H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012
Issues relating to bioequivalence and related administrative procedures
Issues relating to DEA quotas for controlled substances
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3010 - Regulatory Accountability Act of 2011
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2011
In Q4, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Holdings, Inc. , earning $30,000. The report was filed on Jan. 7, 2012.
Original Filing: 300449519.xml
Lobbying Issues
S. 319 - Pharmaceutical Market Access and Drug Safety Act of 2011
Issues relating to bioequivalence and related administrative procedures
Issues relating to DEA quotas for controlled substances
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3010 - Regulatory Accountability Act of 2011
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2011
In Q3, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Holdings, Inc. , earning $30,000. The report was filed on Oct. 5, 2011.
Original Filing: 300410912.xml
Lobbying Issues
S. 319 - Pharmaceutical Market Access and Drug Safety Act of 2011
Issues relating to bioequivalence and related administrative procedures
Issues relating to DEA quotas for controlled substances
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3010 - Regulatory Accountability Act of 2011
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2011
In Q2, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Holdings, Inc. , earning $10,000. The report was filed on July 6, 2011.
Original Filing: 300386294.xml
Lobbying Issues
S. 319 - Pharmaceutical Market Access and Drug Safety Act of 2011
Issues relating to bioequivalence and related administrative procedures
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, The Gibson Group, LLC lobbied for Endo Pharmaceuticals Holdings, Inc. , earning $10,000. The report was filed on April 13, 2011.
Original Filing: 300362993.xml
Lobbying Issues
S. 319 - Pharmaceutical Market Access and Drug Safety Act of 2011
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...